Report Detail

Request for Sample of this report

Pharma & Healthcare Global and China IBS Treatment Market Size, Status and Forecast 2020-2026

  • RnM2359021
    • |
  • 09 October, 2020
    • |
  • Global
    • |
  • 127 Pages
    • |
  • QYResearch
    • |
  • Pharma & Healthcare

Global IBS Treatment Scope and Market Size
IBS Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global IBS Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
IBS-D
IBS-C
IBS-M

Market segment by Application, split into
Hospitals
Clinics
Research Laboratories

Based on regional and country-level analysis, the IBS Treatment market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global IBS Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
Allergan Plc (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals, Inc. (U.S.)
Astellas Pharma Inc. (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals, Inc. (U.S.)
Ardelyx, Inc. (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA, Inc. (Italy)
RedHill Biopharma Ltd. (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Ltd (Japan)
Synthetic Biologics, Inc. (U.S.)
Protagonist Therapeutics Inc. (U.S.)
Pfizer Inc (U.S.)
Lexicon Pharmaceuticals, Inc. (U.S.)
Innovate Biopharmaceuticals (U.S.)


1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 IBS-D
    • 1.2.3 IBS-C
    • 1.2.4 IBS-M
  • 1.3 Market by Application
    • 1.3.1 Global IBS Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Research Laboratories
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global IBS Treatment Market Perspective (2015-2026)
  • 2.2 Global IBS Treatment Growth Trends by Regions
    • 2.2.1 IBS Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 IBS Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 IBS Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top IBS Treatment Players by Market Size
    • 3.1.1 Global Top IBS Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global IBS Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by IBS Treatment Revenue
  • 3.4 Global IBS Treatment Market Concentration Ratio
    • 3.4.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2019
  • 3.5 Key Players IBS Treatment Area Served
  • 3.6 Key Players IBS Treatment Product Solution and Service
  • 3.7 Date of Enter into IBS Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 IBS Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global IBS Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global IBS Treatment Forecasted Market Size by Type (2021-2026)

5 IBS Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global IBS Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global IBS Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America IBS Treatment Market Size (2015-2026)
  • 6.2 North America IBS Treatment Market Size by Type (2015-2020)
  • 6.3 North America IBS Treatment Market Size by Application (2015-2020)
  • 6.4 North America IBS Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe IBS Treatment Market Size (2015-2026)
  • 7.2 Europe IBS Treatment Market Size by Type (2015-2020)
  • 7.3 Europe IBS Treatment Market Size by Application (2015-2020)
  • 7.4 Europe IBS Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China IBS Treatment Market Size (2015-2026)
  • 8.2 China IBS Treatment Market Size by Type (2015-2020)
  • 8.3 China IBS Treatment Market Size by Application (2015-2020)
  • 8.4 China IBS Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan IBS Treatment Market Size (2015-2026)
  • 9.2 Japan IBS Treatment Market Size by Type (2015-2020)
  • 9.3 Japan IBS Treatment Market Size by Application (2015-2020)
  • 9.4 Japan IBS Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia IBS Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia IBS Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia IBS Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia IBS Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Allergan Plc (Ireland)
    • 11.1.1 Allergan Plc (Ireland) Company Details
    • 11.1.2 Allergan Plc (Ireland) Business Overview
    • 11.1.3 Allergan Plc (Ireland) IBS Treatment Introduction
    • 11.1.4 Allergan Plc (Ireland) Revenue in IBS Treatment Business (2015-2020))
    • 11.1.5 Allergan Plc (Ireland) Recent Development
  • 11.2 Sucampo Pharmaceuticals (U.S.)
    • 11.2.1 Sucampo Pharmaceuticals (U.S.) Company Details
    • 11.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
    • 11.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Introduction
    • 11.2.4 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 11.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
  • 11.3 Ironwood Pharmaceuticals, Inc. (U.S.)
    • 11.3.1 Ironwood Pharmaceuticals, Inc. (U.S.) Company Details
    • 11.3.2 Ironwood Pharmaceuticals, Inc. (U.S.) Business Overview
    • 11.3.3 Ironwood Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
    • 11.3.4 Ironwood Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 11.3.5 Ironwood Pharmaceuticals, Inc. (U.S.) Recent Development
  • 11.4 Astellas Pharma Inc. (Japan)
    • 11.4.1 Astellas Pharma Inc. (Japan) Company Details
    • 11.4.2 Astellas Pharma Inc. (Japan) Business Overview
    • 11.4.3 Astellas Pharma Inc. (Japan) IBS Treatment Introduction
    • 11.4.4 Astellas Pharma Inc. (Japan) Revenue in IBS Treatment Business (2015-2020)
    • 11.4.5 Astellas Pharma Inc. (Japan) Recent Development
  • 11.5 Bausch Health
    • 11.5.1 Bausch Health Company Details
    • 11.5.2 Bausch Health Business Overview
    • 11.5.3 Bausch Health IBS Treatment Introduction
    • 11.5.4 Bausch Health Revenue in IBS Treatment Business (2015-2020)
    • 11.5.5 Bausch Health Recent Development
  • 11.6 Abbott Laboratories (U.S.)
    • 11.6.1 Abbott Laboratories (U.S.) Company Details
    • 11.6.2 Abbott Laboratories (U.S.) Business Overview
    • 11.6.3 Abbott Laboratories (U.S.) IBS Treatment Introduction
    • 11.6.4 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 11.6.5 Abbott Laboratories (U.S.) Recent Development
  • 11.7 Synergy Pharmaceuticals, Inc. (U.S.)
    • 11.7.1 Synergy Pharmaceuticals, Inc. (U.S.) Company Details
    • 11.7.2 Synergy Pharmaceuticals, Inc. (U.S.) Business Overview
    • 11.7.3 Synergy Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
    • 11.7.4 Synergy Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 11.7.5 Synergy Pharmaceuticals, Inc. (U.S.) Recent Development
  • 11.8 Ardelyx, Inc. (U.S.)
    • 11.8.1 Ardelyx, Inc. (U.S.) Company Details
    • 11.8.2 Ardelyx, Inc. (U.S.) Business Overview
    • 11.8.3 Ardelyx, Inc. (U.S.) IBS Treatment Introduction
    • 11.8.4 Ardelyx, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 11.8.5 Ardelyx, Inc. (U.S.) Recent Development
  • 11.9 Nestle (Switzerland)
    • 11.9.1 Nestle (Switzerland) Company Details
    • 11.9.2 Nestle (Switzerland) Business Overview
    • 11.9.3 Nestle (Switzerland) IBS Treatment Introduction
    • 11.9.4 Nestle (Switzerland) Revenue in IBS Treatment Business (2015-2020)
    • 11.9.5 Nestle (Switzerland) Recent Development
  • 11.10 Sebela Pharmaceuticals (Ireland)
    • 11.10.1 Sebela Pharmaceuticals (Ireland) Company Details
    • 11.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
    • 11.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Introduction
    • 11.10.4 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2015-2020)
    • 11.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
  • 11.11 Probi (Sweden)
    • 10.11.1 Probi (Sweden) Company Details
    • 10.11.2 Probi (Sweden) Business Overview
    • 10.11.3 Probi (Sweden) IBS Treatment Introduction
    • 10.11.4 Probi (Sweden) Revenue in IBS Treatment Business (2015-2020)
    • 10.11.5 Probi (Sweden) Recent Development
  • 11.12 Alfasigma USA, Inc. (Italy)
    • 10.12.1 Alfasigma USA, Inc. (Italy) Company Details
    • 10.12.2 Alfasigma USA, Inc. (Italy) Business Overview
    • 10.12.3 Alfasigma USA, Inc. (Italy) IBS Treatment Introduction
    • 10.12.4 Alfasigma USA, Inc. (Italy) Revenue in IBS Treatment Business (2015-2020)
    • 10.12.5 Alfasigma USA, Inc. (Italy) Recent Development
  • 11.13 RedHill Biopharma Ltd. (Israel)
    • 10.13.1 RedHill Biopharma Ltd. (Israel) Company Details
    • 10.13.2 RedHill Biopharma Ltd. (Israel) Business Overview
    • 10.13.3 RedHill Biopharma Ltd. (Israel) IBS Treatment Introduction
    • 10.13.4 RedHill Biopharma Ltd. (Israel) Revenue in IBS Treatment Business (2015-2020)
    • 10.13.5 RedHill Biopharma Ltd. (Israel) Recent Development
  • 11.14 AstraZeneca (U.K)
    • 10.14.1 AstraZeneca (U.K) Company Details
    • 10.14.2 AstraZeneca (U.K) Business Overview
    • 10.14.3 AstraZeneca (U.K) IBS Treatment Introduction
    • 10.14.4 AstraZeneca (U.K) Revenue in IBS Treatment Business (2015-2020)
    • 10.14.5 AstraZeneca (U.K) Recent Development
  • 11.15 Ipsen (France)
    • 10.15.1 Ipsen (France) Company Details
    • 10.15.2 Ipsen (France) Business Overview
    • 10.15.3 Ipsen (France) IBS Treatment Introduction
    • 10.15.4 Ipsen (France) Revenue in IBS Treatment Business (2015-2020)
    • 10.15.5 Ipsen (France) Recent Development
  • 11.16 Novartis AG (Switzerland)
    • 10.16.1 Novartis AG (Switzerland) Company Details
    • 10.16.2 Novartis AG (Switzerland) Business Overview
    • 10.16.3 Novartis AG (Switzerland) IBS Treatment Introduction
    • 10.16.4 Novartis AG (Switzerland) Revenue in IBS Treatment Business (2015-2020)
    • 10.16.5 Novartis AG (Switzerland) Recent Development
  • 11.17 Takeda Pharmaceutical Company Ltd (Japan)
    • 10.17.1 Takeda Pharmaceutical Company Ltd (Japan) Company Details
    • 10.17.2 Takeda Pharmaceutical Company Ltd (Japan) Business Overview
    • 10.17.3 Takeda Pharmaceutical Company Ltd (Japan) IBS Treatment Introduction
    • 10.17.4 Takeda Pharmaceutical Company Ltd (Japan) Revenue in IBS Treatment Business (2015-2020)
    • 10.17.5 Takeda Pharmaceutical Company Ltd (Japan) Recent Development
  • 11.18 Synthetic Biologics, Inc. (U.S.)
    • 10.18.1 Synthetic Biologics, Inc. (U.S.) Company Details
    • 10.18.2 Synthetic Biologics, Inc. (U.S.) Business Overview
    • 10.18.3 Synthetic Biologics, Inc. (U.S.) IBS Treatment Introduction
    • 10.18.4 Synthetic Biologics, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 10.18.5 Synthetic Biologics, Inc. (U.S.) Recent Development
  • 11.19 Protagonist Therapeutics Inc. (U.S.)
    • 10.19.1 Protagonist Therapeutics Inc. (U.S.) Company Details
    • 10.19.2 Protagonist Therapeutics Inc. (U.S.) Business Overview
    • 10.19.3 Protagonist Therapeutics Inc. (U.S.) IBS Treatment Introduction
    • 10.19.4 Protagonist Therapeutics Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 10.19.5 Protagonist Therapeutics Inc. (U.S.) Recent Development
  • 11.20 Pfizer Inc (U.S.)
    • 10.20.1 Pfizer Inc (U.S.) Company Details
    • 10.20.2 Pfizer Inc (U.S.) Business Overview
    • 10.20.3 Pfizer Inc (U.S.) IBS Treatment Introduction
    • 10.20.4 Pfizer Inc (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 10.20.5 Pfizer Inc (U.S.) Recent Development
  • 11.21 Lexicon Pharmaceuticals, Inc. (U.S.)
    • 10.21.1 Lexicon Pharmaceuticals, Inc. (U.S.) Company Details
    • 10.21.2 Lexicon Pharmaceuticals, Inc. (U.S.) Business Overview
    • 10.21.3 Lexicon Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
    • 10.21.4 Lexicon Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 10.21.5 Lexicon Pharmaceuticals, Inc. (U.S.) Recent Development
  • 11.22 Innovate Biopharmaceuticals (U.S.)
    • 10.22.1 Innovate Biopharmaceuticals (U.S.) Company Details
    • 10.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
    • 10.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Introduction
    • 10.22.4 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2015-2020)
    • 10.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Summary:
    Get latest Market Research Reports on IBS Treatment . Industry analysis & Market Report on IBS Treatment is a syndicated market report, published as Global and China IBS Treatment Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of IBS Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,900.00
    		$5,850.00
    		$7,800.00
    		3,112.20
    		4,668.30
    		6,224.40
    		3,638.70
    		5,458.05
    		7,277.40
    		599,664.00
    		899,496.00
    		1,199,328.00
    		325,494.00
    		488,241.00
    		650,988.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo